TriangleNCT01805037 · OUTCOME
Percentage of Participants Alive at 2 Years (Overall Survival)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percent of participants
- Interval / dispersion
- 90% Confidence Interval
- Time frame
- From start of treatment to 2 years post treatment discontinuation
What was measured
Overall survival (OS) will be measured from treatment initiation until death from any cause for up to 1 year post-treatment discontinuation. Overall survival is defined as the duration of time from start of treatment to time of death. All patients who have had at least one dose of study treatment will be evaluable for OS. OS will be reported as percentage of participants alive at 2 years post treatment discontinuation, with censoring of patients who are lost to follow-up.
Analysis population: One patient was censored from overall survival because they were lost to follow-up.
Groups in this outcome
Brentuximb Vedotin Dose Level 1 (1.2 mg/kg)
Induction: * Brentuximab vedotin 1.2 mg/kg IV infusion over 30 minutes, weekly x 3 (1 cycle = 4 weeks * Rituximab 375 mg/m2 IV infusion per standard protocol, once weekly for 4 weeks (1 cycle = 4 weeks) Consolidation (optional): Identical to Induction. Maintenance: * Brentuximab vedotin 1.8 mg/kg IV infusion over 30 minutes once every 3 weeks (1 cycle = 3 weeks), for a total of one year from the first induction dose or until progression of disease. * Rituximab 375 mg/m2 IV infusion per standard protocol, once every 6 weeks for a total of one year from the first induction dose or until progression of disease.
| Group | Source count |
|---|---|
| Brentuximb Vedotin Dose Level 1 (1.2 mg/kg) | 19 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Brentuximb Vedotin Dose Level 1 (1.2 mg/kg) | 90 | Not reported | 77 | 100 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 77
- upper Limit
- 100
- value
- 90
- denoms
- counts
- group Id
- OG000
- value
- 19
- units
- Participants
- description
- Overall survival (OS) will be measured from treatment initiation until death from any cause for up to 1 year post-treatment discontinuation. Overall survival is defined as the duration of time from start of treatment to time of death. All patients who have had at least one dose of study treatment will be evaluable for OS. OS will be reported as percentage of participants alive at 2 years post treatment discontinuation, with censoring of patients who are lost to follow-up.
- dispersion Type
- 90% Confidence Interval
- groups
- description
- Induction: * Brentuximab vedotin 1.2 mg/kg IV infusion over 30 minutes, weekly x 3 (1 cycle = 4 weeks * Rituximab 375 mg/m2 IV infusion per standard protocol, once weekly for 4 weeks (1 cycle = 4 weeks) Consolidation (optional): Identical to Induction. Maintenance: * Brentuximab vedotin 1.8 mg/kg IV infusion over 30 minutes once every 3 weeks (1 cycle = 3 weeks), for a total of one year from the first induction dose or until progression of disease. * Rituximab 375 mg/m2 IV infusion per standard protocol, once every 6 weeks for a total of one year from the first induction dose or until progression of disease.
- id
- OG000
- title
- Brentuximb Vedotin Dose Level 1 (1.2 mg/kg)
- param Type
- NUMBER
- population Description
- One patient was censored from overall survival because they were lost to follow-up.
- reporting Status
- POSTED
- time Frame
- From start of treatment to 2 years post treatment discontinuation
- title
- Percentage of Participants Alive at 2 Years (Overall Survival)
- type
- SECONDARY
- unit Of Measure
- percent of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice